Mizutani, Satoshi http://orcid.org/0000-0002-4321-5357
Kodera, Hitoshi
Sato, Yoshiko
Nanki, Toshihiro http://orcid.org/0000-0002-3482-074X
Yoshida, Shunji http://orcid.org/0000-0002-4040-1963
Yasuoka, Hidekata http://orcid.org/0000-0002-2405-6282
Article History
Received: 13 February 2020
Revised: 26 May 2020
Accepted: 28 May 2020
First Online: 6 June 2020
Compliance with ethical standards
:
: SM received lectures fees from Janssen Pharmaceutical K.K.; Bristol-Myers Squibb K.K.; Chugai Pharmaceutical Co.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma K.K.; and Ono Pharmaceutical Co. TN received grant/research support from Chugai Pharmaceutical Co.; Eisai Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Teijin Pharma Ltd.; Eli Lilly Japan K.K.; Bristol-Myers Squibb K.K.; AbbVie GK.; Ono Pharmaceutical Co., Ltd.; Novartis Pharma K.K.; Asahikasei Pharma Corp.; Mitsubishi-Tanabe Pharma Co.; Astellas Pharma Inc.; Ayumi Pharmaceutical Corporation; Pfizer Japan Inc.; Daiichi Sankyo Co., Ltd.; Shionogi & Co., Ltd.; Sanofi K.K.; Nippon Kayaku Co., Ltd.; Yutoku Pharmaceutical Ind. Co., Ltd.; and Actelion Pharmaceutical Japan Ltd.; consultant fees from UCB Japan Co., Ltd.; Eisai Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Gilead Science Inc.; and Chugai Pharmaceutical Co.; and speaker fees from Mitsubishi-Tanabe Pharma Co.; Chugai Pharmaceutical Co.; Eisai Co., Ltd.; Astellas Pharma Inc.; Janssen Pharmaceutical K.K.; Ayumi Pharmaceutical Corporation; Pfizer Japan Inc.; Asahikasei Pharma Corp.; Sanofi K.K., Daiichi Sankyo Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; and AbbVie GK. HY received consulting fees, speaking fees, and/or honoraria from AbbVie GK.; Asahikasei Pharma Corp.; Astellas Pharma Inc.; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; Kissei Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Mitsubishi-Tanabe Pharma Co.; Chugai Pharmaceutical Co.; Novartis Pharma K.K.; Eli Lilly Japan K.K.; Pfizer Japan Inc.; Janssen Pharmaceutical K.K.; Sanofi K.K.; Teijin Pharma Ltd.; Boehringer Ingelheim International GmbH; and Bayer Yakuhin, Ltd.; and research grants from Mitsubishi-Tanabe Pharma Co.; Takeda Pharmaceutical Co.; Daiichi Sankyo Co., Ltd.; Chugai Pharmaceutical Co.; Bristol-Myers Squibb K.K.; MSD K.K.; and Astellas Pharma Inc. HK, YS, and SY have no conflicts of interest to declare.
: We declare that this article has not been published and is not under consideration for publication elsewhere, and that there is no prior publication or the submission elsewhere of any part of the work. All the authors read and approved the final manuscript. This study was approved by the Ethics Committee for Clinical Investigation of the Fujita Health University School of Medicine (no. HM19-193) and the Yokkaichi Hazu Medical Center (no. 108) and was undertaken following the Principles of the Declaration of Helsinki amended during the 64th WMA General Assembly, Fortaleza, Brazil 2013.